3D-printed Rx maker gets $35 million investor

LANGHORNE, Pa. — Aprecia Pharmaceuticals, the company whose 3D-printed anti-epileptic drug Spritam was approved by the Food and Drug Administration in August, announced Thursday that it had received $35 million in funding led by Deerfield Management. 

 

As part of the financing, the company’s outstanding convertible debt was converted into preferred stock, and upon the close of financing, Deerfield partner Jonathan Leff had joined the company’s board of directors. The money is aimed at commercializing Spritam and the development of future 3D-printed drugs that use its ZipDose platform. 

 

“The capital supplied by these prestigious firms, in conjunction with inVentiv Health's continuous commitment to commercialization of Aprecia products, provides the resources required for success as we prepare to transition to a commercial enterprise during the next three to six months,” Aprecia CEO Don Wetherhold said.